Castle Biosciences Shares Rise 55.5% as 2026 Loss Forecast Narrows
Castle Biosciences narrowed its 2026 per-share loss estimate from $1.06 to $0.96 over the past 60 days, reflecting analyst confidence. Shares have climbed 55.5% in six months, driven by three earnings beats in the last four quarters (average surprise 66.11%) and a Zacks Rank #1 (Strong Buy).
1. EPS Forecast Revision
Castle Biosciences’ 2026 estimated loss narrowed from $1.06 to $0.96 per share over the past 60 days, reflecting upward revisions in analyst expectations and improved outlook for its diagnostic product portfolio’s revenue growth.
2. Stock Performance
CSTL shares have advanced 55.5% over the past six months and 21% in the past year, as investors reacted positively to the refined loss projections and strong earnings results.
3. Earnings Beat History
The company delivered earnings above estimates in three of the last four quarters, producing an average surprise of 66.11%, underscoring consistent execution and potential margin improvements.
4. Zacks Rank #1 Status
Castle Biosciences currently holds a Zacks Rank #1 (Strong Buy), driven by favorable revisions in loss estimates and earnings momentum that suggest potential for further upside.